DNLI insider transaction filings

Denali Therapeutics Inc. — 29 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-14. Screen DNLI transaction legs live →

FiledFormInsiderReported transactionsSource
2026-08-144Watts Ryan J. — President and CEO, DirectorGift (G): 32,220 @ $0EDGAR
2026-08-134Schuth Alexander O. — COFO and SecretarySale (S): 2,857 @ $25.07EDGAR
2026-06-054Van Hauwermeiren Timothy — DirectorGrant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0EDGAR
2026-06-054Thornberry Nancy — DirectorGrant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0EDGAR
2026-06-054Cook Jennifer E. — DirectorGrant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0EDGAR
2026-06-054Krognes Steve E. — DirectorGrant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0EDGAR
2026-06-054Schenkein David P — DirectorGrant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0EDGAR
2026-06-054Klein Peter S — DirectorGrant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0EDGAR
2026-06-054FLATLEY JAY T — DirectorGrant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0EDGAR
2026-06-054BAKER BROS. ADVISORS LP — Director
667, L.P. — Director
Baker Bros. Advisors (GP) LLC — Director
Baker Brothers Life Sciences LP — Director
BAKER FELIX — Director
BAKER JULIAN — Director
Grant/award (A): 6,408 @ $0 · Grant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0 · Grant/award (A): 19,226 (derivative) @ $0EDGAR
2026-01-084Schuth Alexander O. — COFO and SecretarySale (S): 17,218 @ $16.50EDGAR
2026-01-084Watts Ryan J. — President and CEO, DirectorSale (S): 35,198 @ $16.50EDGAR
2026-01-054Schuth Alexander O. — COFO and SecretaryGrant/award (A): 57,700 @ $0 · Grant/award (A): 173,100 (derivative) @ $0EDGAR
2026-01-054Watts Ryan J. — President and CEO, DirectorGrant/award (A): 78,960 @ $0 · Grant/award (A): 236,880 (derivative) @ $0EDGAR
2025-12-154BAKER BROS. ADVISORS LP — Director
667, L.P. — Director
Baker Bros. Advisors (GP) LLC — Director
Baker Brothers Life Sciences LP — Director
BAKER FELIX — Director
BAKER JULIAN — Director
Purchase (P): 190,523 (derivative) @ $17.49 · Purchase (P): 2,095,191 (derivative) @ $17.49EDGAR
2025-11-064Van Hauwermeiren Timothy — DirectorGrant/award (A): 10,632 @ $0 · Grant/award (A): 31,897 (derivative) @ $0EDGAR
2025-09-054Watts Ryan J. — President and CEO, DirectorGift (G): 50,000 @ $0EDGAR
2025-08-144Schuth Alexander O. — COFO and SecretarySale (S): 2,937 @ $13.58EDGAR
2025-08-144Ho Carole — Chief Medical OfficerSale (S): 2,937 @ $13.58 · Sale (S): 806 @ $14.64EDGAR
2025-08-074Ho Carole — Chief Medical OfficerOption exercise (M): 44,655 @ $0.68 · Option exercise (M): 44,655 (derivative) @ $0EDGAR
2025-07-114Watts Ryan J. — President and CEO, DirectorOption exercise (M): 455,282 @ $0.68 · Option exercise (M): 40,000 @ $5.28 · Sale (S): 495,282 @ $15 · Option exercise (M): 455,282 (derivative) @ $0 · Option exercise (M): 40,000 (derivative) @ $0EDGAR
2025-06-054Cook Jennifer E. — DirectorGrant/award (A): 6,037 @ $0 · Grant/award (A): 18,111 (derivative) @ $0EDGAR
2025-06-054Thornberry Nancy — DirectorGrant/award (A): 6,037 @ $0 · Grant/award (A): 18,111 (derivative) @ $0EDGAR
2025-06-054Krognes Steve E. — DirectorGrant/award (A): 6,037 @ $0 · Grant/award (A): 18,111 (derivative) @ $0EDGAR
2025-06-054Schenkein David P — DirectorGrant/award (A): 6,037 @ $0 · Grant/award (A): 18,111 (derivative) @ $0EDGAR
2025-06-054Klein Peter S — DirectorGrant/award (A): 6,037 @ $0 · Grant/award (A): 18,111 (derivative) @ $0EDGAR
2025-06-054Tessier-Lavigne Marc — DirectorGrant/award (A): 6,037 @ $0 · Grant/award (A): 18,111 (derivative) @ $0EDGAR
2025-06-054FLATLEY JAY T — DirectorGrant/award (A): 6,037 @ $0 · Grant/award (A): 18,111 (derivative) @ $0EDGAR
2025-06-054BAKER BROS. ADVISORS LP — Director
667, L.P. — Director
Baker Bros. Advisors (GP) LLC — Director
Baker Brothers Life Sciences LP — Director
BAKER FELIX — Director
BAKER JULIAN — Director
Grant/award (A): 10,565 @ $0 · Grant/award (A): 10,565 @ $0 · Grant/award (A): 31,695 (derivative) @ $0 · Grant/award (A): 31,695 (derivative) @ $0EDGAR

Recent 8-K events — Denali Therapeutics Inc.

FiledFormItems reportedSource
2026-08-068-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-288-K2.01 — Completion of Acquisition or Disposition of Assets
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-188-K1.01 — Entry into a Material Definitive Agreement
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-048-K5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-228-K7.01 — Regulation FD DisclosureEDGAR
2026-05-078-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-038-K1.02 — Termination of a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-318-K2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
7.01 — Regulation FD Disclosure
EDGAR
2026-03-258-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-02-268-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=DNLI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →